Cargando…
Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
Ustekinumab is a monoclonal antibody used in Crohn’s disease (CD). Dose optimization in case of non-response and the role of pharmacokinetic–pharmacodynamic (PK-PD) monitoring remain unresolved dilemmas in clinical practice. We aimed to develop a population PK-PD model for ustekinumab in CD and simu...
Autores principales: | Aguiar Zdovc, Jurij, Hanžel, Jurij, Kurent, Tina, Sever, Nejc, Koželj, Matic, Smrekar, Nataša, Novak, Gregor, Štabuc, Borut, Dreesen, Erwin, Thomas, Debby, Vovk, Tomaž, Ostanek, Barbara, Drobne, David, Grabnar, Iztok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538292/ https://www.ncbi.nlm.nih.gov/pubmed/34683880 http://dx.doi.org/10.3390/pharmaceutics13101587 |
Ejemplares similares
-
The Evolving Role of Microsampling in Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Diseases
por: Mingas, Panagiotis-Dimitrios, et al.
Publicado: (2021) -
Sorafenib for the Treatment of Hepatocellular Carcinoma: A Single-centre Real-world Study
por: Hanzel, Jurij, et al.
Publicado: (2020) -
Contemporary Management of Postoperative Crohn’s Disease after Ileocolonic Resection
por: Hanzel, Jurij, et al.
Publicado: (2022) -
Curriculum Mapping of the Master’s Program in Pharmacy in Slovenia with the PHAR-QA Competency Framework
por: Gmeiner, Tanja, et al.
Publicado: (2017) -
Dendritic Cell Profiles in the Inflamed Colonic Mucosa Predict the Responses to Tumor Necrosis Factor Alpha Inhibitors in Inflammatory Bowel Disease
por: Smrekar, Natasa, et al.
Publicado: (2018)